Experimental stem cell therapy targets ALS in single patient
NCT ID NCT04514952
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a stem cell treatment for amyotrophic lateral sclerosis (ALS), a progressive nerve disease. It involved one patient who received their own fat-derived stem cells to try to control the disease. The treatment is no longer available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
River Oaks Hospital and Clinics
Houston, Texas, 77027, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new rowing seat help veterans with paralysis row freely?
- Can filtering the blood slow ALS in patients with a rogue antibody?
- Custom-Made genetic drug takes aim at rare form of ALS
- Tailored genetic drug takes aim at a rare form of ALS
- Custom-Made genetic drug takes aim at rare form of ALS
- Spinal cord cell transplant aims to slow ALS